Search Results
Jun 01, 2024, 23:56 ET Live from ASCO 2024 | Ascentage Pharma Releases Updated Data of FAK/ALK/ROS1 Inhibitor APG-2449 in Patients with NSCLC
Europe, and China. Ascentage Pharma has been designated for multiple Major National R&D Projects, including five Major New Drug Projects, one New Drug Incubator status, four Innovative Drug Programs, and one Major Project for the Prevention
More news about: Ascentage Pharma
Jun 01, 2024, 20:25 ET Jacobio Pharma Presents SHP2 Plus KRAS G12C Data at ASCO
China. Andrea Gillam-Wang M.D., Ph.D., Chief Medical Officer and Global Head of R&D of Jacobio, said: "Our R&D efforts have been focusing on patient needs. We look forward to testing this novel combination against standard care chemotherapy and
More news about: Jacobio Pharma
Jun 01, 2024, 20:17 ET CStone Announces European Medicine Agency CHMP Recommends Approval of Cejemly® (sugemalimab, anti-PD-L1) as First-Line Treatment for NSCLC
domestic anti-PD-L1 mAb in ex-China markets. Dr. Jason Yang, CEO, President of R&D, and Executive Director at CStone, said, "The positive opinion from EMA CHMP normally indicates an upcoming approval for market authorization by the
More news about: CStone
Jun 01, 2024, 20:00 ET Innovent Announces Data from Pivotal Phase 2 TRUST-I Study of Taletrectinib（ROS1 Inhibitor) are Published in the JCO and Reported at 2024 ASCO Annual Meeting
continued to show robust activity in patients with disease that spread to the brain, as well as in patients with acquired resistance mutations, including G2032R. After median follow-up of 23.5 months in TKI-naïve patients, median duration of response (IRC-assessed) and median progression-free survival
More news about: Innovent Biologics
Jun 01, 2024, 20:00 ET Innovent Presents at the 2024 ASCO Annual Meeting on Clinical Data of anti-CLDN18.2 ADC (IBI343) in Patients with Advanced Pancreatic Cancer or Biliary Tract Cancer
therapeutic field. We will continue to follow up on the clinical data update of IBI343. As one of the few biopharmaceutical companies with leading R&D capabilities in both immunotherapy (IO) and antibody-drug conjugates (ADCs), we will also explore combination therapy of IBI343 and its therapeutic
More news about: Innovent Biologics
Jun 01, 2024, 20:00 ET Innovent Presents Phase 1 Clinical Data of First-in-class PD-1/IL-2α Bispecific Antibody Fusion Protein (IBI363) in Melanoma, Colorectal Cancer and other Solid Tumors at the 2024 ASCO Annual Meeting
ophthalmology and other major diseases, presented the Phase 1 clinical data of its first-in-class PD-1/IL-2α bispecific antibody fusion protein (R&D code: IBI363) in advanced solid tumors at the 2024 ASCO Annual Meeting (ClinicalTrials.gov, NCT05460767). More updated data from the Phase 1 study
More news about: Innovent Biologics
Jun 01, 2024, 14:08 ET Thrive with GBA | The Bay to Bay Dialogue held to deepen mutual understanding between China and US
Guangdong and California have reached an agreement in controlling emission of methane, including strengthening R&D in emission control, technical pathways and the establishment of rubust monitoring systems. This year marks the 10th anniversary for the establishment
More news about: GDToday
Jun 01, 2024, 13:42 ET Thrive with GBA | The Bay to Bay Dialogue held to deepen mutual understanding between China and US
Guangdong and California have reached an agreement in controlling emission of methane, including strengthening R&D in emission control, technical pathways and the establishment of rubust monitoring systems. This year marks the 10th anniversary for the establishment
More news about: GDToday
Jun 01, 2024, 11:51 ET CStone Announces European Medicine Agency CHMP Recommends Approval of Cejemly® (sugemalimab, anti-PD-L1) as First-Line Treatment for NSCLC
domestic anti-PD-L1 mAb in ex-China markets. Dr. Jason Yang, CEO, President of R&D, and Executive Director at CStone, said, "The positive opinion from EMA CHMP normally indicates an upcoming approval for market authorization by the
More news about: CStone Pharmaceuticals
Jun 01, 2024, 09:00 ET Hyundai Motor America Reports May 2024 Sales
assembly plant, the all-new Hyundai Motor Group Metaplant America (in development in Georgia), and several cutting-edge R&D facilities. These operations, combined with those of Hyundai's 835 independent dealers, contribute $20.1 billion annually
More news about: Hyundai Motor America
Jun 01, 2024, 07:10 ET Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for 2L+ EGFRm NSCLC based on HARMONi-A Clinical Trial: Positive Trend Observed in Overall Survival towards Ivonescimab Plus Chemotherapy
commercialization of the world's first or best-in-class innovative biological medicines. Founded in 2012, the company has created a unique integrated R&D innovation system with the comprehensive end-to-end drug development platform (ACE Platform) and bi-specific antibody drug development technology (Tetrabody)
More news about: Akeso, Inc.
Jun 01, 2024, 05:55 ET ZEEKR Announces May 2024 Delivery Update
model. With a mission to create the ultimate mobility experience through technology and solutions, ZEEKR's efforts are backed by strong in-house R&D capabilities, a deep understanding of products, high operational flexibility, and a flat, efficient organizational structure. Together, these features
More news about: ZEEKR Intelligent Technology Holding Limited
May 31, 2024, 18:31 ET Class Action Announcement for Doximity, Inc. (DOCS): Kessler Topaz Meltzer & Check, LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Doximity, Inc.
https://www.ktmc.com/new-cases/doximity-inc?utm_source=PR&utm_medium=link&utm_campaign=docs&mktm=r You can also contact attorney
More news about: Kessler Topaz Meltzer & Check, LLP
May 31, 2024, 17:09 ET First results from late-breaking Phase 3 PALOMA-3 study show five-fold reduction in infusion-related reactions with five-minute subcutaneous amivantamab administration
with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion (ex19del) or L858R mutations. Study results showed non-inferior efficacy and pharmacokinetics for SC amivantamab combined with lazertinib compared to intravenous (IV) administration,
More news about: Johnson & Johnson
May 31, 2024, 17:08 ET CMP Investors Have Opportunity to Lead Compass Minerals International, Inc. Securities Fraud Lawsuit
rights or interests with respect to the pending class action lawsuit, please contact Frank R. Cruz, of The Law Offices of Frank R. Cruz, 2121 Avenue of the Stars, Suite 800, Century City, California 90067 at
More news about: The Law Offices of Frank R. Cruz, Los Angeles
May 31, 2024, 16:59 ET NARI Investors Have Opportunity to Lead Inari Medical, Inc. Securities Fraud Lawsuit
rights or interests with respect to the pending class action lawsuit, please contact Frank R. Cruz, of The Law Offices of Frank R. Cruz, 2121 Avenue of the Stars, Suite 800, Century City, California 90067 at
More news about: The Law Offices of Frank R. Cruz, Los Angeles
May 31, 2024, 16:57 ET RYBREVANT® (amivantamab-vmjw) plus lazertinib is the only chemotherapy-free regimen showing longer progression-free survival versus osimertinib in first-line treatment of patients with high-risk EGFR-mutated non-small cell lung cancer
and significantly improved progression-free survival (PFS) compared to osimertinib in patients with NSCLC with EGFR exon 19 deletion (ex19del) or L858R mutations. These data were presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (
More news about: Johnson & Johnson
May 31, 2024, 16:29 ET LNC Investors Have Opportunity to Lead Lincoln National Corporation Securities Fraud Lawsuit
rights or interests with respect to the pending class action lawsuit, please contact Frank R. Cruz, of The Law Offices of Frank R. Cruz, 2121 Avenue of the Stars, Suite 800, Century City, California 90067 at
More news about: The Law Offices of Frank R. Cruz, Los Angeles
May 31, 2024, 16:14 ET LI Investors Have Opportunity to Lead Li Auto Inc. Securities Fraud Lawsuit
rights or interests with respect to the pending class action lawsuit, please contact Frank R. Cruz, of The Law Offices of Frank R. Cruz, 2121 Avenue of the Stars, Suite 800, Century City, California 90067 at
More news about: The Law Offices of Frank R. Cruz, Los Angeles
May 31, 2024, 16:08 ET Blood-based MRD Test for Cancer Recurrence Can Generate Cost Savings in Colorectal Cancer Treatment, Finds Study in JAMA Health Forum
significant factor affecting budget, based on our analysis," said lead author Yonghong Li, PhD, Director, Science and R&D, Quest Diagnostics. "If more than 50% of patients who are eligible are tested, cost savings may even be higher." The analysis had several limitations,
More news about: Quest Diagnostics
May 31, 2024, 16:01 ET Wayne Savings Bancshares, Inc. and Main Street Financial Services Corp. Complete Merger
Street Bank Corp. ("Main Street Bank"), jointly announced today the closing of their previously announced merger. Mark R. Witmer, the Executive Chairman of Main Street, the resulting institution, said, "This is an exciting day for us as we combine two community banks
More news about: Main Street Financial Services Corp
May 31, 2024, 14:03 ET Gramy z najlepszymi: firma Haier występuje w Paryżu w charakterze oficjalnego partnera turnieju Roland-Garros
międzynarodowych wydarzeń w świecie tenisa. PARYŻ, 31 maja 2024 r. /PRNewswire/ -- Haier, wiodąca marka w sektorze urządzeń AGD*, pojawia się u boku największych mistrzów tenisa jako oficjalny partner turnieju
More news about: Haier Group
May 31, 2024, 14:00 ET SHCR Investors Have Opportunity to Lead Sharecare, Inc. Securities Fraud Lawsuit
rights or interests with respect to the pending class action lawsuit, please contact Frank R. Cruz, of The Law Offices of Frank R. Cruz, 2121 Avenue of the Stars, Suite 800, Century City, California 90067 at
More news about: The Law Offices of Frank R. Cruz, Los Angeles
May 31, 2024, 12:55 ET XCMG Machinery prezentuje ekologiczne i inteligentne urządzenia nowej generacji podczas wydarzenia w Xuzhou z udziałem 1200 zaproszonych gości z ponad 60 krajów i regionów
XUZHOU, Chiny, 31 maja 2024 r. /PRNewswire/ -- W ośrodku, gdzie odbywają się kompleksowe testy urządzeń firmy w Jia Wang, Xuzhou, Chiny, spółka
More news about: XCMG Machinery
May 31, 2024, 12:50 ET CoinFund Announces Pledge to Protocol Guild
of net income earned from CESR™, the composite ether staking rate, to support Protocol Guild's membership of over 170 Ethereum Layer 1 R&D maintainers. In 2023, CoinFund announced the launch of CESR in partnership with CoinDesk Indices. Due to its
More news about: CoinFund